Virtual screening and ADMET analysis in identification of new human 17,20-lyase (CYP17A1) inhibitors

The article describes the development of a robust pharmacophore model and pharmacophore screening of poten tial inhibitors of the 17,20-lyase activity of the human CYP17A1 enzyme – an important target in the treatment of prostate cancer. To choose the compounds with the best pharmacokinetics parameters ADMET analysis was performed. According to the calculated data of flexible molecular docking, there were found five compounds with low free energies of binding to the catalytic center of the enzyme, which are comparable to the experimental value of the CYP17A1 inhibitor abiraterone used in clinical practice for treatment castration-resistant prostate cancer. It was established that the connection of the identified compounds with the enzyme is due to van der Waals, lipophilic, electrostatic and intermolecular hydrogen bonds with amino acid residues of the active center and π-stacking with the heme group of the enzyme. The results obtained will be used to develop new drugs with minor side effects for the treatment of prostate cancer due to inhibition of the 17,20-lyase activity of CYP17A1.

1. Wrobel T., Jorgensen F. S., Pandey A. V., Grudzinska A., Sharma K., Yakubu J., Bjorkling F. Non-steroidal CYP17A1 inhibitors: discovery and assessment. Journal of Medicinal Chemistry, 2023, vol. 66, no. 10, pp. 6542–6566. https://doi.org/10.1021/acs.jmedchem.3c00442

2. Gumede N. J., Nxumalo W., Bisetty K., Gilabert L. E., Medina-Hernandez M. J., Sagrado S. Prospective computational design and in vitro bio-analytical tests of new chemical entities as potential selective CYP17A1 lyase inhibitors. Bioorganic Chemistry, 2020, vol. 94, art. 103462. https://doi.org/10.1016/j.bioorg.2019.103462

3. Prostate cancer: treatment and diagnosis. N. N. Alexandrov National Cancer Centre of Belarus. URL: https://omr.by/lechenie-opukholej/urologicheskie-opukholi/rak-predstatelnoj-zhelezy (accessed 11 June 2024) (in Russian).

4. Bird I. M., Abbott D. H. The hunt for a selective 17,20 lyase inhibitors: learning lessons from nature. Journal of Steroid Biochemistry and Molecular Biology, 2016, vol. 163, pp. 136–146. https://doi.org/10.1016/j.jsbmb.2016.04.021

5. Bonomo S., Hansen C. H., Petrunak E. M., Scott E. E., Styrishave B., Jørgensen F. S., Olsen L. Promising tools in prostate cancer research: selective non-steroidal cytochrome P450 17A1 inhibitors. Scientific Reports, 2016, vol. 6, no. 1, art. 29468. https://doi.org/10.1038/srep29468

6. Petrunak E. M., Rogers S. A., Aubé J., Scott E. E. Structural and functional evaluation of clinically relevant inhibitors of steroidogenic cytochrome P450 17A1. Drug Metabolism and Disposition, 2017, vol. 45, no. 6, pp. 635–645. https://doi.org/10.1124/dmd.117.075317

7. Dzichenka Y. V. Computer Modeling of the Structure and Reactivity of Molecules. Minsk, 2023. 139 p. (in Russian).

8. Tyagi R., Singh A., Chaudhary K. K., Yadav M. Pharmacophore modeling and its applications. Bioinformatics, 2022, vol. 1, pp. 269–289. https://doi.org/10.1016/B978-0-323-89775-4.00009-2

9. Matsunaga N., Kaku T., Ojida A., Tanaka T., Hara T., Yamaoka M., Kusaka M., Tasaka A. C(17,20)-lyase inhibitors. Part 2: design, synthesis and structure-activity relationships of (2-naphthylmethyl)-1H-imidazoles as novel C(17,20)-lyase inhibitors. Bioorganic and Medicinal Chemistry, 2004, vol. 12, no. 16, pp. 4313–4336. https://doi.org/10.1016/j.bmc.2004.06.016

10. Kaku T., Matsunaga N., Ojida A., Tanaka T., Hara T., Yamaoka M., Kusaka M., Tasaka A. 17,20-Lyase inhibitors. Part 4: design, synthesis and structure-activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors. Bioorganic and Medicinal Chemistry, 2011, vol. 19, no. 5, pp. 1751–1770. https://doi.org/10.1016/j.bmc.2011.01.017

11. Mafethe O., Ntseane T., Dongola T. H., Shonhai A., Gumede N. J., Mokoena F. Pharmacophore model-based virtual screening workflow for discovery of inhibitors targeting Plasmodium falciparum Hsp90. ACS Omega, 2023, vol. 8, no. 41, pp. 38220–38232. https://doi.org/10.1021/acsomega.3c04494

12. Deora G. S., Joshi P., Rathore V., Kumar K. L., Ohlyan R., Kandale A. Pharmacophore modeling and 3D QSAR analysis of isothiazolidinedione derivatives as PTP1B inhibitors. Medicinal Chemistry Research, 2012, vol. 22, pp. 3478– 3484. https://doi.org/10.1007/s00044-012-0349-7

13. Jain S. V., Ghate M., Bhadoriya K. S., Bari S. B., Sugandhi G., Mandwal P. 3D-QSAR pharmacophore modeling and in silico screening of phospholipase A2α inhibitors. Medicinal Chemistry Research, 2012, vol. 22, pp. 3096–3108. https://doi.org/10.1007/s00044-012-0316-3

14. ADMETlab 3.0. Available at: https://admetlab3.scbdd.com (accessed 17 June 2024).

15. Cheong E. J. Y., Nair P. C., Neo R. W. Y., Tu H. T., Lin F., Chiong E., Esuvaranathan K., Fan H., Szmulewitz R. Z., Peer C. J., Figg W. D., Chai C. L. L., Miners J. O., Chan E. C. Y. Slow-, tight-binding inhibition of CYP17A1 by abiraterone redefines its kinetic selectivity and dosing regimen. Journal of Pharmacology and Experimental Therapeutics, 2020, vol. 374, no. 3, pp. 438–451. https://doi.org/10.1124/jpet.120.265868